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1. Introduction 
The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of chronic 
systemic disorders characterized by muscle inflammation and progressive muscle weakness. 
The major clinical variants are dermatomyositis (DM) including a distinct juvenile (JDM) 
subtype, polymyositis (PM), and inclusion body myositis (IBM) (Engel & Hohlfeld, 2004). 
IBM is divided into sporadic IBM (sIBM), the most common muscle disease starting after 
age 50 years, occurring mainly in men and leading to severe disability, and hereditary 
inclusion body myopathy, characterized by pathologic alterations resembling those of sIBM 
except for a lack of muscle inflammation (hence “myopathy” instead of “myositis”) 
(Askanas & Engel, 1998). DM may occur in children or adults and is considered a 
humorally-mediated microangiopathy, while PM occurs mainly after the second decade of 
life and is a T cell-mediated disease characterized by cytotoxic attack against non-necrotic 
muscle fibers (Dalakas, 2011c). For all IIM forms, both target antigens and triggering factors 
for autoimmune response remain unknown. A growing body of evidence suggests that 
genetically susceptible individuals probably develop an idiopathic inflammatory myopathy 
in response to particular environmental stimuli (Feldman et al., 2008; Needham & Mastaglia, 
2007; O’Hanlon et al., 2006; O’Hanlon & Miller, 2009; Rider et al., 2010; Sarkar et al., 2005; 
Vegosen et al., 2007). 
2. Clinical aspects 
2.1 Dermatomyositis 
DM is a rare multisystemic autoimmune disease that affects children and adults of both 
sexes (with females more commonly affected than males) and all ethnic groups (Amato & 
Barohn, 2009; Mantegazza & Bernasconi, 2005; Mantegazza et al., 1997). It is characterized 
clinically by progressive symmetrical proximal muscle weakness and specific skin 
manifestations, including Gottron’s papules, heliotrope rash, and macular erythema. The 
skin manifestations may precede myositis onset by months or years and can be worsened by 
exposure to ultraviolet light (UVA or UVB) (Hengstman et al., 2000; Love et al., 2009). This 
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photosensitivity appears associated with the TNF-┙-308A allele of the tumor necrosis factor-
 (TNF-) gene, present at high frequency in adult and juvenile Caucasian DM patients 
(Santmyire-Rosenberger & Dugan, 2003).  
Major differences between juvenile and adult DM include the presence of subcutaneous 
calcinosis affecting the elbows and knees with or without ulceration, vasculopathy affecting 
various regions of the gastrointestinal tract, acquired lipodystrophy and related metabolic 
abnormalities (insulin resistance, acanthosis nigricans and type 2 diabetes), and lung disease 
(Kao et al., 2011). Extramuscular manifestations comprise joint contractures, dysphagia, 
cardiopathy, arthralgia, Raynaud’s phenomenon and pulmonary symptoms. Furthermore, 
DM is associated with an underlying malignancy in about 24% of cases, in particular with 
an adenocarcinoma of the ovary, lung, or gastrointestinal tract, as well as with other 
systemic autoimmune, viral or connective tissue diseases (Dalakas & Hohlfeld, 2003). 
2.2 Polymyositis 
The diagnosis of PM is often delayed because of lack of distinguishing clinical features 
(Amato & Barohn, 1997; Dimachkie, 2011). The diagnosis is mainly one of exclusion: absence 
of skin rash, no extraocular or (generally) facial muscle involvement, no family history of 
neuromuscular disease, no history of exposure to myotoxic drugs/toxins, no 
endocrinopathy, no neurogenic disorder, no muscular dystrophy, and no biochemical 
muscle disease (such as muscle enzyme deficiency) (Dalakas, 2007b). Patients present neck 
flexor and symmetric proximal arm and leg weakness that typically develops sub-acutely 
over weeks to months (Amato & Barohn, 1997). Distal muscles may become involved but to 
a lesser degree than proximal muscles. Dysphagia occurs in a third of patients, and mild 
facial weakness is occasionally present. The extraocular muscles are spared, sensation is 
normal and muscle stretch reflexes are usually preserved. PM on its own is rare; it is usually 
seen in association with interstitial lung disease or polyarthritis. The risk of malignancy with 
PM is lower than DM, but may be slightly higher than in the general population (Amato & 
Barohn, 1997; Dimachkie, 2011). 
2.3 Inclusion body myositis 
Sporadic IBM (sIBM) is the most common IIM in patients over 50 years old, although 
symptoms can start up to 20 years earlier (Dalakas, 2007b; Needham & Mastaglia, 2007). 
Because onset is insidious and disease course slow, disease onset and disease incidence are 
difficult to establish. IBM is more common in males (male to female ratio 3:1) and in 
Caucasians than Afro-Americans (Needham & Mastaglia, 2007).  
Characteristic features of sIBM are atrophy and weakness of wrist and finger flexors and 
quadriceps. Dysphagia is common, occurring in up to 60% of cases and can be severe 
enough to interfere with nutrition or give rise to episodes of choking. Although most 
patients have no sensory symptoms, evidence of generalized peripheral neuropathy is 
present in up to 30% of patients on clinical examination and electrophysiological testing. As 
many as 15% of sIBM patients have an underlying autoimmune disorder (systemic lupus 
erythematosus, Sjögren syndrome, scleroderma, sarcoidosis, variable immunoglobulin 
deficiency or thrombocytopenia). However, unlike DM and PM, sIBM is not associated with 
myocarditis, lung disease or increased risk of malignancy (Amato & Barohn, 2009).  
Although IBM is considered acquired, familial cases have been described, some associated 
with leukoencephalopathy. Lack of responsive to immunosuppressive therapy in suspected 
PM patients gives rise to the suspicion of IBM (Mantegazza & Bernasconi, 2005). 
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3. Autoantibodies 
High titers of autoantibodies are present in the serum of 60-80% of IIM patients (Suber et al., 
2008; Ghirardello et al., 2010). These may be myositis-specific (MSAs) – highly specific for 
particular IIM subtypes – or myositis-associated. Myositis-associated autoantibodies may 
also by present in patients with other autoimmune diseases and overlap syndromes (Suber 
et al., 2008). Most MSAs target ubiquitously expressed cytoplasmic or nuclear molecules 
(Ghirardello et al., 2010) with autoantibodies against cytoplasmic aminoacyl-tRNA 
synthetases being particularly common (Mammen, 2010). Autoantibodies against histidyl-
tRNA synthetase are found in 25-30% of IIM patients (Mammen, 2010) and autoantibodies 
against the synthetases of threonyl-tRNA, alanyl-tRNA, glycyl-tRNA, isoleucyl-tRNA, 
asparaginyl-tRNA, tyrosyl-tRNA, and phenylalanyl-tRNA have all been documented 
(Mathews et al., 1984; Bunn et al., 1986; Targoff, 1990; Hirakata et al., 1999; Betteridge et al., 
2007; Targoff, 2008; Zong & Lundberg, 2011). 
Anti-Mi-2 antibodies (Mammen, 2010) are a specific marker for DM, being present in 20-30% 
of adult and juvenile patients. Mi-2 is a major component of the nucleosome-remodeling 
deacetylase (NuRD) complex, which regulates transcription by modifying chromatin 
structure. DM patients with anti-Mi-2 autoantibodies tend to have severe cutaneous 
manifestations, including heliotrope rashes, shawl rashes on the upper back and neck, and 
cuticle overgrowth, but also have a more favourable prognosis, with good response to 
steroid therapy, and low incidence of malignancy compared to DM patients without anti-
Mi-2 antibodies (Mammen, 2010). Anti-Mi-2 antibody positivity seems to occur more 
frequently at lower latitudes, and it has been found that in human keratinocyte cell lines 
exposed to UV Mi-2 protein expression is upregulated. It has therefore been proposed that 
UV drives the autoimmune response against Mi-2. This suggestion is in line with the 
observation that increased Mi-2 protein levels are often found in DM muscle biopsies, while 
in normal and PM muscle biopsies, Mi-2 protein levels are relatively low (Casciola-Rosen et 
al., 2005). 
Autoantibodies against components of the signal recognition particle (SRP) are reported in 
4-6% of patients with PM/DM. The SRP is a highly conserved constitutively expressed 
cytoplasmic ribonucleoprotein, consisting of six polypeptides and a single 7SL RNA 
(Ghirardello et al., 2010). The SRP complex is involved in the translocation of nascent 
secretory or membrane proteins across the endoplasmic reticulum. Histopathological 
features of patients with antibodies against SRP are prominent muscle fibre necrosis and 
regeneration, without significant inflammatory cell infiltration, and, as in DM, a reduced 
number of capillaries, that are enlarged, and show deposits of membrane attack complex 
(MAC) (Targoff, 2008).  
Anti-p155/140 antibodies are found in 20-30% of DM and JDM patients; these recognize 
nuclear transcriptional intermediary factor 1-gamma (TIF1-┛) and are associated with severe 
skin involvement and high risk of developing cancer (Ghirardello et al., 2010). Anti-small 
ubiquitin-like modifier activating enzyme (SAE) antibodies are found in about 8% of DM 
patients (Ghirardello et al., 2010). A novel MSA – anti-CADM-140 antibody – was identified 
recently in a Japanese cohort of DM patients (Nakashima et al., 2010). These antibodies seem 
particularly associated with clinically amyopathic DM who also have acute progressive 
interstitial lung disease. The antigen target of anti-CADM-140 antibody was found to be 
RNA helicase C domain-containing protein 1 (IFIH1), also known as melanoma 
differentiation associated protein-5 (MDA-5), one of the RIG-I-like receptors involved in the 
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recognition of viral RNAs during the innate immune responses. RIG-I and IFIH1 interact 
with viral RNA and mediate signalling pathways leading to the transcription of type I 
interferons (IFNs) and inflammatory cytokines (Takeuchi & Akira, 2008). The finding that 
IFIH1 provokes MSA reinforces the idea of an association between myositis and viral 
infection: self-tolerance might be broken when IFIH1 interacts with certain viral RNAs and 
generates cryptic epitopes or when elevated IFN-┚ levels up-regulate IFIH1 synthesis, 
resulting in over-expression and release from damaged cells (Nakashima, 2010). 
It is not well understood how a self-molecule can be singled out as target for autoantibody 
response. It may occur as a consequence of the proinflammatory properties of molecule 
itself or as a result of modifications to autoantigen structure occurring during cell damage or 
cell death (Suber et al., 2008). Structural changes in self-molecules generally result in 
modification of antigen processing and presentation and also to activate immune responses 
against epitopes not generated during tolerance induction. In myositis tissues, a common 
alteration in molecular structure is that induced when cells are killed by the release of 
cytotoxic enzymes by CD8+ T cells, especially granzyme B (Casciola-Rosen et al., 1999). 
4. Treatments 
The main concerns about drug treatment for IIMs are that controlled trials are few and there 
are no standardized outcome measures to reflect changes in disability or quality of life 
(Distad et al., 2011). The main treatments for PM and DM are drugs that suppress or modify 
the immune system (Distad et al., 2011). Oral corticosteroids (in particular a high dose of 
prednisone) represent the first-line medications used to manage these conditions. When the 
treatment with these drugs is prolonged for a long period, or when the disease reveals 
refractory to therapy, a second-line agent, usually a chronic, steroid-sparing 
immunosuppressive drug such as azathioprine, methotrexate, cyclosporine, 
cyclophosphamide, and mycophenolate mofetil is added. Such medications often allow 
corticosteroid dosages to be reduced, but monitoring is required for their own side effects, 
such as bone marrow suppression, kidney dysfunction, and respiratory concerns. 
Intravenous immunoglobulin has also been reported effective by some controlled studies 
(Basta & Dalakas, 1994; Saadeh et al., 1995; Cherin et al., 1994; Sansome & Dubowitz, 1995, 
as cited in Choy & Isenberg, 2002), producing clinical improvement together with reduction 
in complement deposition, membrane attack complex formation, inflammation, fibrosis, 
cytokines, chemokines and adhesion molecules, especially in DM patients (Dalakas, 2011a).  
Rituximab, a monoclonal antibody that depletes B cells, has also shown efficacy in 
uncontrolled studies on DM patients and is a promising treatment for the disease (Noss et 
al., 2006; Levine, 2005). Other treatments currently under study include new agents 
targeting intracellular T-cell signalling pathways (associated with antigen recognition and 
costimulation), B cells or B cell growth factors. Monoclonal antibodies against components 
of the complement pathway, inhibitors of TNF- and IFN-, and antagonists of the IL-1 
receptor are also under study. 
5. Pathology 
PM and sIBM are characterized by the presence of an endomysial mononuclear cell infiltrate 
mainly consisting of activated (HLA-DR+, LFA-1+) cytotoxic CD8+ T lymphocytes with a 
memory phenotype (CD45RO+). The infiltrate surrounds and eventually invades non-
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necrotic muscle fibers. When CD8+ T cells are in close contact with muscle fibers, perforin 
and granzyme containing granules accumulate within the T cells close to the point of contact 
(polarization), and are eventually released at the immunological synapse that forms 
between the T cell and the fiber. Sporadic IBM is also characterized by abnormal 
accumulation of proteins within the muscle fibers. 
The muscle pathology of DM is characterized by presence of infiltrates consisting of both B 
cells, T cells and plasmacytoid dendritic cells, together with perifascicular muscle fiber 
atrophy. CD4+ T cells are prominent perivascularly; CD4+ plasmacytoid dendritic cells 
spread through the endomysial, perimysial, and perivascular regions (Greenberg et al., 
2005a). Membrane attack complex (MAC) deposition can be observed on capillaries where it 
is thought to induce capillary depletion, leading to muscle fiber necrosis and the 
perifascicular atrophy pathognomic for DM even in the absence of inflammation. It has been 
proposed that in DM perifascicular myofiber damage mainly occurs as a result of chronic 
overproduction of /-interferon-inducible proteins (Greenberg et al., 2005a; Greenberg, 
2007b & 2008). However this seems unlikely as the damaged fibers display all the markers of 
regeneration and tissue remodeling (Dalakas, 2011c), suggesting that the expression of these 
proteins is a consequence and not the cause of the regeneration process. The chronic 
overproduction of /-interferon-inducible proteins hypothesis is also difficult to reconcile 
with the reduction in number of capillaries and early activation and deposition of MACs on 
capillaries before perifascicular atrophy is evident (Dalakas, 2011c). Furthermore up-
regulation of /-interferon-inducible genes is not specific to DM: it also occurs in PM and 
other connective tissue diseases (Cappelletti et al., 2011; Walsh et al., 2007). 
6. Immunopathogenesis 
6.1 Dermatomyositis 
The etiology of DM is not clearly understood. It has been suggested that DM develops as a 
result of a combination of autoimmune reactions in genetically susceptible individuals in 
response to environmental triggers such as infectious agents (Batthish & Feldman, 2011). 
6.1.1 Complement activation and vascular endothelial damage 
The most striking characteristic of DM is early and persisting damage to the vascular 
endothelium of endomysial capillaries, and, to a lesser extent, of larger blood vessels 
(Greenberg & Amato, 2004; Dalakas, 2011c) (Fig. 1). The earliest observed anomaly is 
deposition of MAC on small arterioles and capillaries supplying the muscle fibers. This may 
be observed before inflammatory or structural changes. Thus, microscopic blood vessel 
damage appears to be complement-mediated; however the mechanism of complement 
activation remains unclear. It has been suggested that the presence of antibodies against 
endothelial cells (Dalakas, 2011c) activates C3 leading to the formation of C3b and C4b 
fragments and subsequently C5b-9. Deposition of the membranolytic C5b-9 complex on the 
walls of intramuscular arterioles and capillaries and increased expression of intercellular 
adhesion molecules by capillary endothelial cells have been reported in several studies 
(Kissel et al., 1986; Whitaker & Engel, 1972, as cited in Greenberg & Amato, 2004), although 
data are conflicting regarding the frequency of these occurrences and their specificity for 
DM (Greenberg & Amato, 2004). Other suggestions are that complement activation is 
secondary to injury to the vascular endothelium or, alternatively, that the membrane attack 
complexes derive from plasma where they circulate in the form of immune complexes.  
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Fig. 1. Major pathological features of DM muscle. Muscle biopsy shows upregulation of 
major histocompatibility complex class I (MHC-I) on the surface of the majority of fibers, 
and perivascular invasion by CD4+ T cells and CD68+ macrophages. BDCA2+ plasmacytoid 
dendritic cells (pDCs) – natural interferon-producing cells – are present in endomysial 
regions. Regenerating myofibers are often present in perifascicular regions. 
Irrespective of where complement activation occurs in the chain of pathological events, the 
result is a marked reduction in the number of capillaries per muscle fiber followed by the 
compensatory dilatation of the lumen of the remaining capillaries (Dalakas, 2006a) (Fig. 1). 
The endothelial cells become swollen and necrotic, and develop tubuloreticular inclusions 
and microvacuoles. These alterations result in perivascular inflammation, muscle ischemia 
and the characteristic perifascicular atrophy (Fig. 1). It is frequently stated that the 
perifascicular atrophy is a direct consequence of hypoperfusion of the vulnerable 
perifascicular regions of the muscle fascicles (Dalakas, 2006a), implying that DM is a true 
microvasculopathy (Hohlfeld & Dornmair, 2007; Probst-Cousin et al., 2010). Gene 
expression studies have demonstrated that both angiogenic and angiostatic genes are 
expressed in juvenile and adult DM muscle. In particular, angiostatic factors, including 
inducible protein 10 kDa (IP-10 or CXCL10), monokine induced by IFN (MIG/CXCL9), and 
IFN-inducible T-cell  chemoattractant (I-TAC/CXCL11), have been detected in peripheral 
blood during active disease and at high levels in muscle biopsies from untreated patients. In 
untreated patients they correlate with the extent of capillary loss and mononuclear cell 
infiltration (Baechler et al., 2007; Bilgic et al., 2009; Fall et al., 2005). Neovascularization 
(V┚3-positive capillaries) is suggested to occur later in the disease and is more prevalent in 
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JDM than adult DM (Nagaraju et al., 2006). Transcript levels of genes involved in 
endothelial cell adhesion (cathepsin B, CD146), proliferation (cyclin D1), differentiation 
(jagged protein), migration (hepatocyte growth factor) and angiogenesis (ITPR1, HIF1A, 
angiogenic inducer 61) are up-regulated in DM patients compared to controls, suggesting 
that affected muscle possesses all the molecules required for the initiation of angiogenic 
response (Nagaraju et al., 2006). Notwithstanding increased expression of pro-angiogenic 
factors in DM, the vascular network does not recover and symptoms persist. To explain this 
it has been suggested that the capillary damage is so great that microvascular neogenesis is 
unable to effect a restoration of the microvasculature, or that the potency of the angiogenesis 
inhibitors exceeds that of the angiogenic factors. Alternatively the angiogenic stimuli may 
not be sufficiently co-coordinated to exert an overall positive effect. It is also possible that 
the anti-endothelial immune response and toxicity damage the endothelial cells to such an 
extent that they are unable to respond to the angiogenic stimuli (Konttinen et al., 2004). 
6.1.2 Type I interferons 
Type I IFNs have only recently been recognized to play a role in DM, particularly JDM, 
pathogenesis (Feldman et al., 2008). Gene expression profiling of muscle samples from 
untreated juvenile and adult DM patients showed that almost half of the most differentially 
expressed genes were associated with immune responses, and most of these were inducible 
by type I IFNs (Tezak et al., 2002; Greenberg et al., 2002; Greenberg et al., 2005a; Salajegheh 
et al., 2010a; Cappelletti et al., 2011). Among these, transcript levels of 15 kDa interferon-
stimulated ubiquitin-like modifier protein (ISG15), interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3), and myxovirus resistance protein A (MxA) – three 
important mediators of biological and therapeutic effects of type I IFNs – were significantly 
higher in affected muscle than controls (Greenberg et al., 2002; Greenberg et al., 2005a; 
Salajegheh et al., 2010a; Cappelletti et al., 2011), and these higher levels were directly 
associated with muscle weakness, but not with the extent or severity of inflammatory skin 
involvement, suggesting muscle-specific pathophysiology (O’Connor et al., 2006).  
Increased serum levels of type I IFN-inducible -type CXC chemokines (IP-10, MIG, and I-
TAC) and monocyte chemoattractant proteins (MCP-1, MCP-2, MIP-1, MIP-1) have been 
found in a number of patients with severe forms of DM (Bilgic et al., 2009; Khanna & Reed, 
2010). These proinflammatory molecules appear to result in angiostasis in affected tissues by 
acting as chemoattractants to recruit CXCR3-bearing lymphocytes to sites of inflammation 
in muscle and skin (Fall et al., 2005; De Paepe et al., 2005).  
Although type I IFNs are critical for the host immune response, several lines of evidence 
suggest that these cytokines are directly involved in the onset of autoimmunity, as 
demonstrated by the appearance of autoimmune phenomena following high-dose IFN 
therapy (Hall & Rosen, 2010). Type I IFNs are able to influence the induction of an adaptive 
immune response through the activation and maturation of dendritic cells (DCs) and the 
subsequent production of high levels of proinflammatory cytokines and chemokines, such 
as IL-8, IL-6, IL-1, CCL3 and CCL4 (Hall & Rosen, 2010). IFN-/ are also involved in the 
expression of MHC class I and II molecules, as well as of costimulatory molecules on DCs, 
promoting an efficiently activation of T cells. 
6.1.3 Innate immunity and Toll-like receptors  
The innate immune system is the first line of defense against invading organisms. In 
addition to cellular and humoral components, the innate immune system has also 
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anatomical structures that act as barriers to pathogen infection (Mayer, 2006). Unlike 
adaptive immunity, which is antigen specific and requires some time to react to an invading 
organism, the innate immune response is not antigen specific and it is activated within a few 
hours of exposure to almost any microbe. The main characteristic of innate immunity is that 
it recognizes pathogen molecules that contain specific molecular patterns – pathogen-
associated molecular patterns (PAMPs). Molecules thus recognized include 
lipopolysaccharide (LPS) from the Gram-negative bacteria cell wall, peptidoglycan and 
lipoteichoic acids from the cell wall of Gram-positive bacteria, mannose, bacterial and viral 
unmethylated CpG DNA, bacterial flagellin, the amino acid N-formylmethionine found in 
bacterial proteins, double and single stranded RNA from viruses, and glucan from fungal 
cell wall. 
Recognition of PAMPs depends on a series of soluble pattern-recognition receptors (PRRs) 
that circulate in blood or are associated with the membrane of various cell types, including 
macrophages, mast cells, lymphocytes and DCs. The most important PRRs that activate the 
innate immune response are cytoplasmic RNA helicases, including RIG-I, Mda-5 and LGP2, 
and Toll-like receptors (TLRs) (Kumar et al., 2011). TLR3, TLR7 and TLR9 – a subfamily of 
TLRs localized in endolysosomes - have been found to be the most potent promoters of type 
I IFN production. TLR3 is expressed by DCs and macrophages, as well as non-immune cells 
including fibroblasts, epithelial and skeletal muscle cells (Schreiner et al., 2006); TLR7 and 
TLR9 are expressed by mDCs and pDCs (Kawai & Akira, 2010). 
A recent study on endosomal TLR involvement in IIM pathogenesis (Cappelletti et al., 2011) 
found that the pattern of expression of TLR3, TLR7 and TLR9 differed between DM and PM, 
suggesting distinct disease mechanisms in these two forms of myopathy. In DM, numerous 
TLR3-expressing mDCs were identified among immune infiltrating cells in the endomysial 
space and around blood vessels; these cells are probably associated with IFN- 
overproduction, which is a peculiar feature of DM. It was also found that TLR3 was 
prominently expressed on the vascular endothelial cells of capillaries in DM, plausibly as a 
primary response to capillary injury caused by a still unknown factor. It was suggested that 
TLR3 production was responsible for the chronic overexpression of type I IFNs in DM, 
reinforcing the older idea that this form of myopathy is a microvasculopathy. It was also 
suggested that TLR3 is actively involved in the neoangiogenic process, since it was observed 
on pathological and neovascular structures in both DM and JDM. Moreover, in JDM, where 
muscle fiber regeneration is prominent, as revealed by antibody against developmental 
myosin heavy chain antibody (MHCdev), numerous TLR3+ MHCdev+ fibers were 
identified, particularly in atrophic perifascicular areas (Cappelletti et al., 2011). This finding 
confirms ongoing regeneration in these muscle regions and supports the idea of TLR3 
involvement in the regeneration or differentiation of damaged muscle. In this view, TLR3 
could be responsible for the induction of several immune mediators, which would be in turn 
involved in the remodelling of the area and not just in the atrophic process as previously 
suggested. 
6.2 Polymyositis 
Polymyositis is an autoimmune disease principally characterized by T-cell-mediated injury 
(Fig. 2). While factors responsible for inducing such damage have been identified in some 
autoimmune conditions, the mechanisms of the immune reaction in PM remain poorly 
understood (Liang et al., 2000). 
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Fig. 2. Polymyositis is a T-cell-mediated autoimmune disease. The main pathological 
features are the presence of perimysial and endomysial mononuclear cell infiltrates (mainly 
cytotoxic CD8+ T lymphocytes) surrounding or invading non-necrotic MHC-I and MHC–II-
positive muscle fibers. CD138-positive plasma cells are also abundant in endomysial areas 
and are probably the main source of autoantibodies in PM muscle. 
6.2.1 Immunological synapse between T cells and muscle fibers 
The immunological synapse is a specialized cell-cell junction between T cell and antigen-
presenting cell surfaces. The specificity of T cell recognition is determined by engagement of 
the T cell receptor (TCR) on T cells with the cognate peptide-MHC complex presented by the 
antigen-presenting cells (Dustin et al., 2010b; Dustin & Long, 2010a; Jenkins & Griffiths, 
2010). The contact point between the TCR and the antigen-MHC complex lies in 
complementarity-determining region 3 (CDR3), consisting of the V-(D)-J combination. If the 
TCR recognizes a presented antigen, the amino acid sequence of the CDR3 region is 
conserved in the activated T cells (García et al., 1999 and Davis et al., 1998, as cited in 
Mantegazza & Bernasconi, 2005). 
The TCR repertoire in IIM patients has been investigated by various methods, including 
CDR3 spectratyping, laser microdissection combined with single-cell PCR of individual 
myocytotoxic T cells, and immunohistochemistry (Hofbauer et al., 2003; Benveniste et al., 
2004; Bender et al., 1995; Mantegazza et al., 1993). These studies have shown that, in IBM 
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and PM in particular, distinct clones of T cells expand in muscle (Hofbauer et al., 2003; 
Bender et al., 1995; Mantegazza et al., 1993) after exposure to specific local antigens and 
persist there for long periods (Benveniste et al., 2004). TCR gene usage has also been 
investigated in other organs involved by inflammation in IIMs: T cell expansion was 
demonstrated in CD4+ and CD8+ cells obtained by bronchoalveolar lavage fluid but not in 
peripheral blood cells. This finding, together with the finding of a biased TCR V-gene usage 
in muscle, seems to suggest a shared specific, antigen-induced response in these target 
organs (Englund et al., 2007). 
Class I and II MHC upregulation is an early and consistent finding in the skeletal muscle of 
IIM patients and is an essential prerequisite for the interaction of muscle with infiltrating 
CD8+ and CD4+ T cells, and for the formation of an immunological synapse (Fig. 2). In 
order for an antigen-specific T-cell response to be activated, the MHC I- and II-expressing 
muscle fibers also need to express costimulatory molecules. In PM and IBM, BB-1 but not 
B7-1 or B7-2 have been found in the cytoplasm of N-CAM-positive regenerating fibers and 
also in areas remote from inflammation (Murata & Dalakas, 1999; Bernasconi et al., 1998); at 
the same time autoinvasive CD8+ T cells have been found to present CD28 and CTLA-4 
counter receptors. CD28 and CTLA-4 counter receptors are similar to each other in overall 
structure, but are expressed differently and have different functions. CD28 is usually 
expressed on resting T cells and when it binds to B7 promotes T cell activation and the 
subsequent production of cytokines, cytokine receptors and genes for cell survival (Reiser & 
Stadecker, 1996). By contrast, CTLA-4 is expressed only on activated T cells and its binding 
to B7 results in an inhibitory signal that blocks further T cell activation (Reiser & Stadecker, 
1996). The implication of simultaneous CD28 and CTLA-4 expression of T cells in IIMs is not 
well understood. It is possible that the balance between these molecules depends on many 
factors including disease stage, and type or length of treatment (Nagaraju et al., 1999).  
Recently, however, CD4+ and CD8+ CD28null T cells have also been reported in muscle-
infiltrating cells of DM and PM patients (Fasth et al., 2009). In addition to releasing cytotoxic 
granules and inducing MHC I and II upregulation in muscle fibers, these cells are 
considered to be potent inducers of TNF and IFN- – proinflammatory cytokines that exert 
myotoxic effects and interfere with the contractile properties of muscle fibers (Fasth et al., 
2009). It has been suggested that the differentiation of T cells into CD28null occurs in the 
inflamed muscle as a result of the local production of IFN- by resident pDCs. 
The fact that muscle fibers also express the CD40 costimulatory molecule constitutes 
additional evidence that these fibers act as non-professional antigen presenting cells (APCs) 
in PM. Interaction of CD40 with its ligand CD40L on infiltrating T cells has been shown to 
induce leukocyte adhesion and cytokine production: VCAM, ICAM, thrombospondins, 
MMP-9 and MMP-2 metalloproteinases, interleukin(IL)-6, IL-8 and IL-15, are all produced 
and serve to enhance T cell activation and differentiation (Dalakas, 2001 & 2011b). 
Immunological synapse formation and T cell polarization toward professional or non-
professional APC requires cytoskeletal reorganization and microtubule-organizing centers 
(Lasserre & Alcover, 2010; Billadeau et al., 2007). F-actin and actin-associated proteins are 
also recruited to establish the interaction between the T cell and target cell. Secretory 
vesicles are transported along microtubules to dock with the T cell membrane during 
maturation of immunological synapse – a process involving dyneins and kinesins 
(Stinchcombe et al., 2006; Dustin, 2010a). The kinesin motor protein KIF4 was recently 
shown to play a role in the interaction between muscle fiber and T cell infiltrates in IIM 
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(Bernasconi et al., 2008). In particular, KIF4 was upregulated in IIM muscle biopsies and 
KIF4-positive cells were abundant in mononuclear cells surrounding individual muscle 
fibers. Furthermore, KIF4 involvement in lytic granule delivery to the muscle cell-T cell 
interaction site is suggested by the finding that, in activated PBLs in vitro, KIF4 colocalized 
with lysosome-associated membrane protein 1 (marker of lytic vesicles) and also to a 
considerable extent with the perforin normally present in these vesicles (Bernasconi et al., 
2008). 
6.2.2 Cytokines, chemokines and activation of the innate immune response 
Cytokines and chemokines, soluble chemical messengers communicating between immune 
cells and tissue cells, are essential players in leukocyte activation and migration (Borish & 
Steinke, 2003). A wide range of these inflammatory molecules (e.g. IL-1 and 1, IL-2, IL-4, 
IL-6, IL-10, IL-17, TNF-, IFN-/, IFN-, and TGF-) is expressed at elevated levels in the 
muscle and blood of IIM patients (De Paepe et al., 2009; Mantegazza & Bernasconi, 2005). IL-
1, IL-1 and IFNs seem to play a critical role in IIM pathogenesis. IL-1 is localized on the 
endothelial cells of capillaries and on some infiltrating inflammatory cells in PM and DM 
muscle. IL-1 transcripts are highly up-regulated in IBM and PM muscle, and IL-1 protein 
localizes to myofibers in areas of severe inflammation and also in endomysial infiltrates. 
IFNs are a large family of regulators of innate and adaptive immunity, with documented 
antiviral properties (De Paepe et al., 2009). Type I IFNs (comprising IFN-, IFN-, IFN-, 
IFN- and IFN-) and type III IFNs (also known as IFN-s) are produced by almost all 
nucleated cells and mediate potent antiviral effects. Type II IFN (i.e. IFN-) is produced only 
by natural killer cells, natural killer T cells and T cell populations, which is involved in the 
modulation of the adaptive immune response. 
IFN- transcript expression has been shown up-regulated in PM muscle compared to other 
IIM and also control muscle (Cappelletti et al., 2011), emphasizing the involvement of IFN- 
in the induction of MHC class II molecules present on muscle fibers in PM muscle. IFN- is 
also involved in the synthesis of important chemotactic cytokines that govern leukocyte 
migration from blood to sites of inflammation (CCL2, CXCL9 and CXCL10) and sustain the 
active invasion of nonnecrotic myofibers by inflammatory cells (Confalonieri et al., 2000; De 
Bleecker et al., 2002; Raju et al., 2003, as mentioned in Mantegazza & Bernasconi, 2005).  
The high levels of IFN-, as well as of IL-4 and IL-17, present in PM muscle, suggest 
involvement of activated CD4+ T cells in the pathophysiology of this disorder. A recent 
study (Kim et al., 2010) demonstrated a significant direct correlation between the expression 
of these proinflammatory cytokines and the expression of TLR2, TLR4 and TLR9 in IIMs. 
TLR2 activation is involved in induction of the Th2 immune response; while TLR4 induces 
Th1 and Th17 immune responses; TLR9 is also involved in the Th1 immune response (Re & 
Strominger, 2001; Agrawal et al., 2003; Dillon et al., 2004; Redecke et al., 2004; Abdollahi-
Roodsaz et al., 2008, as cited in Kim et al., 2010). Thus, the TLR overexpression found in IIM 
muscle points to involvement of innate immunity in the pathogenesis of these diseases and 
is likely to be a link between innate and adaptive immunity in IIMs.  
Immunohistochemical and molecular studies have shown that transcriptionally active 
CD138+ plasma cells – that have undergone affinity maturation and switched their isotype 
from IgM to IgG or IgA – are abundant in PM muscle (Greenberg, 2007a; Salajegheh et al., 
2010b; Cappelletti et al., 2011). In view of the recently demonstrated ability of TLR9 to 
induce B cells to mature to plasma cell in vitro (Giordani et al., 2009), together with the 
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observed upregulation of TLR9 in this form of myopathy (Cappelletti et al., 2011), it is 
reasonable to hypothesize a role for this receptor in immunoglobulin production in PM. 
6.3 Sporadic inclusion body myositis 
Sporadic IBM is the most common muscle disease in older persons. Triggering factors for 
this form of myopathy are not well understood and no enduringly effective treatment has 
been found. 
Factors pointing an immunopathogenic mechanism in sIBM include association with other 
autoimmune diseases (Koffman et al., 1998), association with common variable 
immunodeficiency and increased levels of natural killer cells (Dalakas et al., 1995), and 
occurrence of autoantibodies at similar levels to those seen in classic autoimmune disorders 
(Badrising et al., 2004) (Fig. 3). sIBM is also often seen in same generation family members, 
as occurs with other autoimmune disorders, and there is a strong association with certain 
human leukocyte antigen (HLA) genes (Badrising et al., 2004).  
Furthermore, sIBM is characterized by strong up-regulation of cytokines, chemokines and 
their receptors both as transcripts and proteins in muscle (Figarella-Branger et al., 2003),  
 
 
Fig. 3. Pathophysiology of sIBM. sIBM is a multifactorial disease presenting autoimmune 
and degenerative features. Mononuclear cell inflammation (CD8+ cytotoxic T cells), 
endoplasmic reticulum stress, dysregulation of protein folding mechanisms (heat shock 
protein upregulation), mitochondrial abnormalities and possibly inhibition of the 
autophagic pathway (LC3 upregulation), are salient features of this myopathy. 
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together with ubiquitous overexpression of MHC class I antigen and costimulatory 
molecules on muscle fibers, even those not invaded by inflammatory infiltrating cells 
(Dalakas, 2006b). Immunological synapses between muscle fibers and clonally expanded 
autoinvasive CD8+ T cells are also present in sIBM muscle (Fig. 3). These CD8+ T cells 
express perforin and other lytic enzymes. Dendritic cells (mainly mDCs) and CD138+ plasma 
cells are also abundant in the endomysium of sIBM muscle (Greenberg et al., 2005b; 
Cappelletti et al., 2011). Finally, it is worth noting that IBM-like myopathy can be associated 
with HIV and HTLV-1 infection (Dalakas et al., 2007a) and also with post-polio syndrome 
(Parissis et al., 2003) suggesting the possibility of a viral trigger to the autoimmunity of sIBM. 
sIBM also shows several features typical of degenerative diseases (Fig. 3). These include 
presence of vacuoles (mainly in muscle fibers not invaded by T cells) and intracellular 
deposition of ubiquitinated, multiprotein aggregates in vacuole-free regions of muscle 
cytoplasm (Askanas et al., 2009). These aggregates contain amyloid-, phosphorylated tau, 
several proteins (-synuclein, presenilin-1 and cellular prion protein) that tend to  
 
 
 
Fig. 4. Proposed immunopathogenetic mechanisms in DM. Activation of type I interferon 
pathway, together with overexpression of endosomal Toll-like receptors (TLRs), suggests 
the possibility of a viral or bacterial trigger to onset. In DM, the primary site of infection 
seems to be the microvascular endothelium, reinforcing the idea that the disease is primarily 
a microvasculopathy. The presence of TLR3 on neovascular structures and regenerating 
myofibers in adult and juvenile DM muscle tissue suggests a possible protective role for this 
receptor or its involvement in the regeneration or differentiation of damaged muscle tissue. 
Over-expression of type I IFNs might be involved in muscle fiber atrophy. 
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Fig. 5. Proposed immunopathogenetic mechanisms in PM. In PM upregulation of type I and 
type II IFNs, possibly caused by a pathogenic agent or by intracellular autoantigens released 
during myocyte damage, may be responsible for TLR7 and TLR9 activation in dendritic cells 
(both myeloid and plasmacytoid), macrophages and plasma cells. Induction of TLR9 may 
sustain the autoimmune process by increasing immunoglobulin production as well as 
contributing to antigen presentation. 
unfold/misfold to form -pleated sheet and a number of other proteins of varying function, 
including: (i) markers of oxidative stress; (ii) endoplasmic reticulum chaperones, signs of the 
unfolded protein response (UPR); (iii) 26S proteasome components and proteasome shuttle 
protein p62; (iv) mutated ubiquitin (UBB+1); (v) heat shock proteins; (vi) nuclear-related 
proteins such as TDP-43, and other transduction and transcription factors.  
It is unknown whether the autoimmune or protein dysregulation process constitutes the 
primary event; a plausible hypothesis is that both develop as a consequence of still 
unknown causative agent or agents (Karpati & O’Ferrall, 2009). 
7. Conclusion 
The principal clinical and pathological features of the three main types of IIM have been 
described together with evidence regarding pathogenetic mechanisms. Dermatomyositis is 
considered a microvasculopathy, characterized by injury to the capillary endothelium 
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leading to depletion of capillaries in muscle; the damage to muscle manifests as 
perifascicular atrophy and is accompanied by inflammatory cell stress. In DM the findings 
that type I interferon-associated genes are up-regulated and TLR3 overexpressed suggest 
that a pathogen infection may be a triggering factor for this myopathy (Fig. 4). In PM recent 
findings that plasma cells are abundant in the endomysium and that immunoglobulin genes 
are up-regulated suggest that a humoral immune response to tissue injury is important in 
this disorder and that the ideas that PM as an exclusively T cell-mediated myopathy 
requires revision (Fig. 5). Sporadic IBM is a degenerative muscle disease, with no effective 
treatment, characterized by the coexistence of autoimmune and protein conformation 
abnormalities. New investigations in the protein dysregulation processes of this disease 
hold the hope that effective treatments may soon be found (Henriques-Pons & Nagaraju, 
2009). 
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